Sylvia Krallmann

Director Global Quality Risk Management at Stada Group

Sylvia Krallmann has a diverse range of work experience. Sylvia started their career in 2008 as a Pharmaceutical Trainee in Research & Development at Kneipp. Following that, they worked as a Pharmaceutical Trainee at Berlin-Apotheke an der Charité in 2009. From 2010 to 2015, Sylvia worked on duty in various pharmacies. Since 2015, Sylvia has been with the STADA Group, where they have held multiple roles. Sylvia began as a Junior Manager in QA GMP Master Documentation and then progressed to becoming a Team Leader/Manager in QA GMP Master Documentation for CMO. In 2019, they were promoted to Head Global Quality Product Risk Management, and as of 2023, they are the Director of Global Quality Risk Management at STADA Group. Throughout these positions, Sylvia has been involved in areas such as risk analysis, quality warnings, process optimization, regulatory compliance, and coordination of inspections.

Sylvia Krallmann obtained a PhD in Medical Research (Dr. rer. medic.) from the University of Cologne in 2015. Prior to that, they were a PhD student at the University of Cologne's Laboratory of Molecular Hematology and Oncology, where they pursued their Doktor (Ph.D.) degree from 2010 to 2014. In 2009, they completed their Approbation/Licensure as a pharmacist at The Philipp University of Marburg. Sylvia had previously earned their Bachelor's degree in Pharmacy (Pharmazie) from the same university from 2004 to 2008.

Location

Frankfurt, Germany

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Stada Group

14 followers

Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.


Industries

Employees

10,000+

Links